Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48 combined with VP16 for HER2-expressing platinum-sensitive recurrent ovarian cancer after PARP inhibitor
ChiCTR2500104910Phase 4Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jun 2025
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of disitamab vedotin and etoposide in ovarian cancer, sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Objective Response Rate. Started Jun 2025; status: recruiting.
02
Drugs
disitamab vedotinetoposide
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on ChiCTR2500104910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104910.